Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MYD88 L265P IMO-8400 B-cell lymphoma sensitive detail...
Unknown unknown IT-901 B-cell lymphoma not applicable detail...
Unknown unknown Ibrutinib + Ublituximab + Umbralisib B-cell lymphoma not applicable detail...
EZH2 A677G EZH2 Y111D Tazemetostat B-cell lymphoma resistant detail...
EZH2 A677G EZH2 Y111D GSK126 B-cell lymphoma resistant detail...
Unknown unknown KTE-C19 B-cell lymphoma not applicable detail...
Unknown unknown HMPL-523 B-cell lymphoma not applicable detail...
Unknown unknown Denileukin diftitox + Sirolimus B-cell lymphoma not applicable detail...
Unknown unknown Denileukin diftitox + Temsirolimus B-cell lymphoma not applicable detail...
Unknown unknown Alisertib B-cell lymphoma not applicable detail...
Unknown unknown JCAR017 B-cell lymphoma not applicable detail...
Unknown unknown Fenretinide B-cell lymphoma not applicable detail...
Unknown unknown CPI-1205 B-cell lymphoma not applicable detail...
Unknown unknown SKLB-23bb B-cell lymphoma not applicable detail...
Unknown unknown Loncastuximab tesirine B-cell lymphoma not applicable detail...
Unknown unknown Alisertib + Rituximab B-cell lymphoma not applicable detail...
Unknown unknown Alisertib + Rituximab + Vincristine B-cell lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01084252 Phase Ib/II Isatuximab Dexamethasone + Isatuximab Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Active, not recruiting
NCT01109069 Phase II Ibrutinib Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Active, not recruiting
NCT01307267 Phase I Utomilumab + Rituximab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed
NCT01695941 Phase I Alisertib + Bortezomib + Rituximab Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma Active, not recruiting
NCT01799889 Phase II Entospletinib A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies Active, not recruiting
NCT01859819 Phase II Cytarabine + Rituximab Treatment for Advanced B-Cell Lymphoma Recruiting
NCT01976585 Phase Ib/II CDX-301 + poly ICLC In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy Recruiting
NCT02006485 Phase I Ublituximab + Umbralisib Ibrutinib Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies Active, not recruiting
NCT02018861 Phase I Itacitinib INCB039110 + INCB050465 Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide INCB050465 A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting
NCT02106091 Phase I AFM11 Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL Suspended
NCT02153580 Phase I Etoposide Cyclophosphamide + Fludarabine Bendamustine Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia Recruiting
NCT02207062 Phase I Ibrutinib Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma Recruiting
NCT02253992 Phase Ib/II Nivolumab + Urelumab Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma Active, not recruiting
NCT02254772 Phase Ib/II Ipilimumab + SD-101 TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma Completed
NCT02266147 Phase Ib/II SD-101 Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma Completed
NCT02272686 Phase II Ibrutinib Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma Terminated
NCT02290951 Phase I REGN1979 A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies Recruiting
NCT02328014 Phase Ib/II ACP-319 Acalabrutinib ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies Active, not recruiting
NCT02343120 Phase I BGB-3111 Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Recruiting
NCT02395601 Phase I CPI-1205 A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas Active, not recruiting
NCT02436707 Phase II Ibrutinib Cisplatin + Dexamethasone + Gemcitabine + Rituximab Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma Recruiting
NCT02443077 Phase III Cyclophosphamide Carmustine + Cytarabine + Etoposide + Melphalan Ibrutinib Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Suspended
NCT02500407 Phase I Atezolizumab + BTCT4465A A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Recruiting
NCT02569476 Phase I BGB-3111 + Obinutuzumab BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies Active, not recruiting
NCT02600897 Phase Ib/II lenalidomide + Obinutuzumab + Polatuzumab Vedotin A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT02611323 Phase Ib/II Obinutuzumab + Polatuzumab Vedotin + Venetoclax A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Recruiting
NCT02624986 Phase Ib/II Idasanutlin + Obinutuzumab A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting
NCT02628405 Phase Ib/II R2-ICE R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma Recruiting
NCT02631044 Phase I JCAR017 Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) Recruiting
NCT02706405 Phase I Cyclophosphamide + JCAR014 + MEDI4736 JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Recruiting
NCT02715843 Expanded access MT-3724 Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma Available
NCT02733042 Phase Ib/II Rituximab lenalidomide + MEDI4736 + Rituximab Bendamustine + MEDI4736 + Rituximab Ibrutinib + MEDI4736 Durvalumab A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) Active, not recruiting
NCT02846935 Phase 0 Decitabine + Tetrahydrouridine p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Completed
NCT02875002 Phase I Belinostat + Volasertib Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Withdrawn
NCT02898259 Phase Ib/II Ixazomib + Lenalidomide + Rituximab Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma Recruiting
NCT02914938 Phase I ME-401 ME-401 + Rituximab A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Recruiting
NCT02924402 Phase I XmAb13676 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Recruiting
NCT02950220 Phase I Pembrolizumab + Ibrutinib Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting
NCT02973113 Phase I EB-VST cells + Nivolumab Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE) Recruiting
NCT02992522 Phase I Lenalidomide + Obinutuzumab + Venetoclax Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Recruiting
NCT02997761 Phase II Blinatumomab + Ibrutinib Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia Recruiting
NCT03019640 Phase II BEAM + Lenalidomide + Filgrastim + Rituximab Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma Recruiting
NCT03028103 Phase I Tazemetostat + Fluconazole Repaglinide + Omeprazole + Tazemetostat Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects Active, not recruiting
NCT03036904 Phase I Venetoclax + DA-EPOCH-R Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R) Recruiting
NCT03038672 Phase II Nivolumab + Varlilumab Nivolumab Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Recruiting
NCT03133221 Phase II Idelalisib 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Recruiting
NCT03153462 Expanded access KTE-C19 + Fludarabine phosphate + Cyclophosphamide Axicabtagene Ciloleucel Expanded Access Study Available
NCT03217253 Phase I Tazemetostat Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction Recruiting
NCT03223610 Phase I Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma Recruiting
NCT03274492 Phase III Polatuzumab Vedotin R-CHP CHOP + Rituximab A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma Recruiting
NCT03310619 Phase Ib/II Durvalumab + JCAR017 A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM) Recruiting
NCT03328078 Phase I CA-4948 A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting
NCT03410901 Phase I BMS-986178 + SD-101 TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas Recruiting
NCT03424603 Phase I STRO-001 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Recruiting
NCT03488251 Phase II Gemcitabine + MT-3724 + Oxaliplatin PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Recruiting
NCT03579927 Phase Ib/II Filgrastim iC9/CAR.19/IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Not yet recruiting
NCT03589469 Phase II Loncastuximab tesirine Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Recruiting
NCT03605589 Phase I Blinatumomab + Pembrolizumab Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma Recruiting
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Not yet recruiting
NCT03704298 Phase Ib/II KTE-C19 + Utomilumab Cyclophosphamide + Fludarabine Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma (ZUMA-11) Recruiting
NCT03704714 Phase Ib/II CHOP + Nivolumab + Rituximab Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Recruiting
NCT03749018 Phase II Nivolumab + REPOCH Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Not yet recruiting
NCT03761056 Phase II KTE-C19 + Fludarabine phosphate + Cyclophosphamide Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) Recruiting
NCT03793140 Phase II CPI-613 A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations Recruiting